[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Acorn Biolabs Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":144},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,58,81,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100610461","early-phase-1-secretome-treatment-for-facial-rejuvenation-100610461",false,"NCT07227883","Secretome Treatment for Facial Rejuvenation","Blinded, Randomized, Controlled, Trial to Evaluate the Efficacy and Safety of Autologous Hair Follicle Secretome for Facial Rejuvenation","Inclusion Criteria\n\n* Male or Female\n* Age: ≥30 and ≤ 75 at the time of consent.\n* Fitzpatrick skin types I-V\n* Moderate to very severe facial aging according to the SASSQ for the categories of elasticity, wrinkles, and skin roughness.\n* Willing to refrain from cosmetic procedures throughout the study period (i.e. laser treatments, chemical peels, microneedling, dermal filler injections, neuromodulator injections, etc.)\n* Willing to use study support products as directed and will not introduce any new skin care or makeup products throughout the study period. Subjects will be provided with a Skincare Kit: Cetaphil Gentle Skin Cleanser 20 oz, Cetaphil Daily Hydrating Lotion 3 oz, Cetaphil Sheer Mineral Liquid Face Sunscreen SPF 50 . Two of each will be provided with application instructions.\n* Male subjects with facial hair must be willing to shave the morning of their treatments\u002Ffollow-up visits.\n* Willing to minimize sun\u002Fultraviolet light exposure for the duration of the study, including all of the following: applying sunscreen daily, at least 15 minutes before going outside; wearing sun-protective clothing (e.g., a hat, sunglasses) when outdoors; reapplying sunscreen every 2 hours during outdoor activities; avoiding tanning bed\u002Ftanning product use.\n* Competent and willing to provide written, informed consent to participate in all study activities\n* Willing and able to tolerate multiple injections and attend all study visits\n* Negative urine pregnancy test result at the time of screening (if applicable)\n* For female subjects of childbearing potential, must be willing to use an acceptable form of birth control (oral contraceptives, hormonal implants, intrauterine device \\[IUD\\], hormonal injectables specifically for birth control, contraceptive patch or ring, tubal ligation \\[tubes tied\\], or total sexual abstinence) during the entire course of the study. All systemic birth control measures (oral, hormonal implants, injectables) must be in consistent use for at least 30 days prior to study enrollment. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and\u002For both ovaries, or has had a bilateral tubal ligation.\n\nExclusion Criteria\n\n* Use of topical tretinoin, adapalene, tazarotene, hydroquinone, imiquimod, 5-fluorouracil, ingenol mebutate, concentrated hydrogen peroxide, diclofenac, vitamin C, alpha hydroxy acids, or photodynamic therapy (PDT) to the face within 4 weeks prior to baseline photography and throughout the study period\n* Dermatologic diseases or conditions (e.g. atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, wounds, infections, irritation, sunburn, windburn, etc.) in the treatment area that could interfere with the study, in the opinion of the Investigator\n* Starting use or stopping use of GLP-1 agonists, or planned weight loss or gain during the study period. Subjects using GLP-1 agonists must be taking the drug for maintenance AND body weight must have been stable for at least 3 months prior to initial study treatment.\n* History of keloid formation, hypertrophic scarring, or abnormal\u002Fdelayed wound healing\n* Previous medical aesthetic rejuvenation treatments on the face, such as chemical peel, dermabrasion, non-ablative or ablative resurfacing procedure, or face-lift with laser or other devices, up to 3 months prior to baseline photography\n* Treatment with neuromodulators in crow's feet, glabellar region, or frontalis muscles within 4 months prior to baseline photography\n* Treatment with dermal fillers, collagen stimulators, fat injections or permanent fillers within the past 6 months prior to baseline photography.\n* Patients using other anti-aging treatments\u002Fprocedures\u002Fsystemic medications or injections administered\u002Fprescribed by a medical professional before starting the study, if the investigator believes they will confound the results. Consulting with Sponsor is encouraged.\n* Heavy smoker (\\>1 pack of cigarettes a day)\n* Energy-based device (i.e., radiofrequency device treatments, microfocused ultrasound device or other ultrasound-based device treatments, laser and light-based device treatments, microneedling) treatment in the treatment area within 6 months prior to baseline photography\n* Currently be taking isotretinoin (Accutane).\n* Subjects on an immunosuppressant or have an autoimmune condition (except stable, controlled Hashimoto's thyroiditis)\n* Surgery (i.e., face lift, eyebrow lift, neck lift or lower rhytidectomy, liposuction, etc.) during the 12-month period prior to baseline photography\n* Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study\n* Severe active infection (e.g. HIV, HepB or C, UTI, etc.)\n* Current or recent (within last 5 years) malignancy (except basal cell and squamous cell skin cancers as long as basal cell was not on the face)\n* History of systemic chemotherapy or radiation within the last 5 years\n* Continuous\u002Fdaily use of nonsteroidal anti-inflammatory or Vitamin E, unless discontinued within 7 days before 1st treatment and only used as needed through the trial period.\n* Anticipated pregnancy or trying to become pregnant in the next year\n* Current anticoagulant therapy (heparins; factor Xa inhibitors; direct agents such dabigatran, rivaroxaban, apixaban, endoxaban and betrixaban; warfarin\u002Fcoumarins). Low dose aspirin and omega-3 supplements allowed.\n* Any other criterion that is based on the clinical judgment of the investigator may place the subject at risk or confound study results",true,"ALL","30 Years","70 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","Secretome treatment for facial rejuvenation",[28,29,30,31],"Facial Aging","Rejuvenation","Stem Cell","Stem Cell Banking",[33,34,35,36,37,38,39,40,41,42,43,44],"stem cells","secretome","autologous","hair follicle","aging","facial","face","under eyes","wrinkles","anti-aging","rejuvenation","regeneration","RECRUITING","2026-04-30",{"date":48,"type":49},"2026-05-04","ACTUAL",{"date":51,"type":49},"2025-12-15",{"date":53,"type":22},"2026-12-20",{"name":55,"class":56},"Acorn Biolabs Inc.","INDUSTRY",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":16,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100552752","autologous-hair-follicle-derived-secretome-as-adjunct-to-aesthetic-procedures-100552752","NCT06477172","Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures","A Multi-site, Prospective, Observational Study of Autologous Hair Follicle Secretome (aHFS) as an Adjunct to Medical Aesthetic Procedures","Inclusion Criteria:\n\n* Male and Female\n* Ages: 18-60\n* Any Fitzpatrick skin type\n* Planning a medical aesthetic procedure\n* For subjects receiving hair procedures (closed to enrollment):\n\n  1. Androgenic alopecia\n  2. Traction alopecia\n  3. Scarring alopecia\n  4. Stable use of any medication or supplement for hair loss, including finasteride, any other 5 α-reductase inhibitor, minoxidil, steroids, or hormonal products, during the 3 months prior to enrollment in the study is allowed.\n  5. No intention to start new hair growth medications or change dose of hair growth medications from the time of consent through the end of the study follow-up period.\n* Undergoing one of the following medical aesthetic procedures:\n\n  1. Laser resurfacing of the face (ablative or non-ablative) or Ellacor of the face (Ellacor closed to enrollment)\n  2. Tixel of the face\n  3. Keralase of the scalp (scalp treatment closed to enrollment)\n  4. Acne Scars and Surgery scars, either old or new as long as old scars are also being treated with ablative or non-ablative laser or microneedling (e.g. abdominoplasty, breast reduction\u002F reconstruction\u002Fenhancement, post-weight loss, etc.\n* Planning to use Acorn Autologous Hair Follicle Secretome cosmetic product\n\nExclusion Criteria:\n\n* Pregnant or Breastfeeding\n* Participation in an interventional clinical trial in the last 30 days\n* Use of other topical cosmetic products that may confound results\n* Use of retinoids within 7 days prior to facial procedure\n* For those receiving hair treatment, must not have had a hair transplant in the treatment area within the past 12 months\n* Any health condition that in the investigator's opinion should preclude participation in study","18 Years",{"count":67,"type":22},500,"OBSERVATIONAL","Non-interventional, multi-site, prospective, open-label, observational, real-world study of autologous hair follicle secretome use.",[71],"Post Procedural Erythema","2026-03-02",{"date":74,"type":49},"2026-03-04",{"date":76,"type":49},"2024-09-09",{"date":78,"type":22},"2027-02",{"name":55,"class":56},40,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":17,"minAge":65,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":57},"100601234","autologous-hair-follicle-secretome-for-androgenic-alopecia-single-site-100601234","NCT07107841","Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)","Blinded, Randomized, Controlled, Trial to Evaluate the Efficacy and Safety of Autologous Hair Follicle Secretome for the Treatment of Androgenic Alopecia (Single Site)","Inclusion Criteria\n\n* SUBJECTS MUST BE ON A STABLE COURSE OF MINOXIDIL (ORAL OR TOPICAL) AND\u002FOR 5-ALPHA REDUCTASE INHIBITORS. THEY MUST HAVE BEEN ON THE SAME 5-ALPHA REDUCTASE INHIBITOR FOR ≥12 MONTHS PRIOR TO BASELINE.\n* FEMALE SUBJECTS MUST NOT BE ON HAIR GROWTH MEDICATIONS OR TOPICALS FOR ≥6 MONTHS PRIOR TO BASELINE.\n* TESTOSTERONE REPLACEMENT THERAPY (TRT) IN ANY FORM (E.G. DEPO-, INJECTABLE, TOPICAL, PATCHES, NASAL GEL, ORAL, PELLET ETC.) IS ALLOWED AS LONG AS SUBJECT HAS BEEN ON A STABLE COURSE (IN THE OPINION OF THE INVESTIGATOR) OF TRT FOR ≥12 MONTHS.\n* Biological sex: Male and Female (up to n=20 males and up to n=10 females will be in each arm for a total of up to n=40 males and up to n=20 females)\n* Age: ≥18 - 65 years\n* Subjects with Androgenic alopecia\n* No intention to start new hair growth medications and no intention to change the dosage or usage of minoxidil or 5-alpha reductase inhibitors until the end of their participation in the trial.\n* Competent and willing to provide written, informed consent to participate in all study activities.\n* Willing and able to tolerate multiple injections of the study product.\n* Must be able to attend all study related clinical visits.\n* Willing to maintain the same hair style as at the Screening Visit for the duration of the study.\n* Must be willing to have small (diameter similar to a pencil lead) UV (invisible) or red colored tattoo dots applied to scalp (up to 5) and touch up tattoos if necessary. UV tattoo dots only show under black light. Subjects will chose UV or red.\n\nExclusion Criteria\n\n* Subjects with clinical diagnosis of alopecia areata or other non-androgenic forms of alopecia.\n* Active skin disease (Psoriasis or severe seborrheic dermatitis) of the scalp\n* Scalp infection\n* Severe active systemic infection\n* Cuts or abrasions on the scalp\n* History of surgical hair restoration in the last 12 months.\n* Current or recent (within last 5 years) malignancy (except basal cell and squamous cell skin cancers)\n* History of systemic chemotherapy or radiation\n* History of thyroid dysfunction\n* History of autoimmune disorder (specifically Graves disease, Hashimoto thyroiditis, or systemic lupus erythematosus)\n* Continuous\u002Fdaily use of nonsteroidal anti-inflammatory or Vitamin E, unless discontinued within 7 days before 1st treatment and only used as needed through the trial period.\n* Use of any medications that potentially cause drug-induced hair loss (e.g., depo-testosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.\n* Known allergy or sensitivity to tattoo ink.\n* Current anticoagulant therapy (heparins; factor Xa inhibitors; direct agents such dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban; warfarin\u002Fcoumarins)\n* Significant tendency to develop keloids or hypertrophic scarring\n* Subjects unable to communicate with the investigator and staff\n* Any health condition that in the investigator's opinion should preclude participation in this study","65 Years",{"count":90,"type":22},60,[92],"NA","(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365.\n\nHair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.",[95,96,97],"Androgenic Alopecia","Alopecia","Baldness",[34,99,100,33,101,102,103,104,105,106,107,36,108],"alopecia","Hair","androgenic","androgenetic","Hormone","scalp","hair loss","baldness","bald","Acorn","2026-02-10",{"date":111,"type":49},"2026-02-12",{"date":113,"type":49},"2025-10-16",{"date":115,"type":22},"2027-09-15",{"name":55,"class":56},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":16,"sex":17,"minAge":65,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":57},"100574856","cryopreserved-hair-follicles-for-disease-and-cell-replacement-100574856","NCT06764719","Cryopreserved Hair Follicles for Disease and Cell Replacement","Characterization of Cryopreserved Plucked Hair Follicles and Generation of Functional Cell Lines for Disease Modeling and Cell Replacement Therapies","Inclusion Criteria:\n\n* Gender: Male or Female.\n* Age: ≥18 and ≤80 years.\n* Language proficiency: Able to read and understand English.\n* Informed consent: Willing to provide written, informed consent to participate in all study activities.\n\nExclusion Criteria:\n\n* Scalp\u002FHair Disorders: Subjects diagnosed with active scalp infections or inflammatory skin conditions.\n* Systemic Conditions: Subjects with chronic illnesses, such as autoimmune diseases or diabetes, that may impact scalp health or wound healing.\n* Medications: Subjects on immunosuppressants, steroids, or other medications associated with hair loss.","80 Years",{"count":126,"type":22},100,"To explore the application of cells expanded from plucked hair follicles after collection, transport, and cryopreservation, in disease modeling and cell-based therapies.",[129,130,131],"Diabetes Mellitus","Sport Injury","Injury Traumatic",[133,33,134,135],"Hair follicles","pluripotent","cell differentiation","2025-09-29",{"date":138,"type":49},"2025-10-02",{"date":140,"type":49},"2025-01-06",{"date":142,"type":22},"2026-03",{"name":55,"class":56},""]